Most people who've heard of alcohol genetics know about ADH1B — the gene behind the "Asian flush." But there's a second, equally important alcohol dehydrogenase variant that operates in the same enzyme family and influences who gets hurt by alcohol and who gets heart-protective benefits. ADH1C encodes the gamma subunit of [alcohol dehydrogenase | The enzyme that catalyzes the first step of alcohol metabolism, converting ethanol to acetaldehyde in the liver] and exists in two functionally distinct forms.

The rs1693482 variant (chromosome 4, position 99342808 on GRCh38) defines the ADH1C*1 (Arg272) and ADH1C*2 (Gln272) alleles. ADH1C*1 encodes a faster enzyme with approximately 2.5-fold higher activity for ethanol oxidation compared to ADH1C*2. This enzymatic speed difference has measurable consequences for alcohol-related cancer risk and for the cardiovascular benefit that some drinkers obtain from moderate alcohol consumption.

The C allele on the genomic plus strand corresponds to ADH1C*1 (Arg272, fast); the T allele corresponds to ADH1C*2 (Gln272, slow). In the older literature, these are called gamma1 (fast) and gamma2 (slow) isoforms. ADH1C*1 predominates in Europeans (~58% C allele frequency) but is highly prevalent in East Asians (~93%) and moderately common in South Asians (~68%) and Latinos (~68%).

The Mechanism

ADH1C is one of three class I alcohol dehydrogenase enzymes (along with ADH1A and ADH1B) that catalyze the [NAD⁺-dependent | Nicotinamide adenine dinucleotide acts as the electron acceptor, being reduced to NADH during ethanol oxidation] oxidation of ethanol to acetaldehyde. The Arg272Gln substitution falls within the catalytic domain and alters the enzyme's kinetic parameters: the ADH1C*1 (gamma1) isoform has a higher Vmax for ethanol oxidation, meaning it generates acetaldehyde faster.

The consequences of this enzymatic speed difference flow in two directions. First, faster acetaldehyde production in heavy drinkers translates to greater cumulative acetaldehyde exposure in tissues like the esophagus, liver, and upper aerodigestive tract — acetaldehyde is a Group 1 human carcinogen and directly damages DNA. Second, in moderate drinkers, the rate of ethanol oxidation influences how long ethanol remains in the bloodstream; slower ADH1C*2 activity may prolong ethanol's presence and enhance its effects on HDL cholesterol and other cardiovascular mediators.

The Evidence

Cancer Risk in Heavy Drinkers:

A study of 818 heavy drinkers¹¹ A study of 818 heavy drinkers
Homann N et al. ADH1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. International Journal of Cancer, 2006 found that the ADH1C*1/*1 (CC) genotype was significantly overrepresented among heavy drinkers who developed malignant tumors compared to those with non-cancerous alcohol-related organ damage. Compared to *1/*1 homozygotes, cancer risks were substantially lower for those with ADH1C*2 alleles, producing the following risk estimates for CC homozygotes: esophageal cancer OR=2.93, hepatocellular cancer OR=3.56, and head and neck cancer OR=2.20.

The mechanism is consistent with the enzyme kinetics: faster acetaldehyde production in ADH1C*1/*1 carriers means more carcinogenic acetaldehyde exposure per unit of alcohol consumed. This effect operates in addition to — and in synergy with — ALDH2 rs671 status, which controls the clearance rate of acetaldehyde.

Alcoholic Liver Disease:

A meta-analysis of 16 case-control studies (1,375 cases, 1,802 controls)²² A meta-analysis of 16 case-control studies (1,375 cases, 1,802 controls)
He L et al. Association between ADH1C gene polymorphism and alcoholic liver cirrhosis risk. PLOS ONE, 2015 found ethnicity-dependent effects: in Asian populations, the *1/*2 genotype increased alcoholic liver cirrhosis risk vs *1/*1 (OR=1.63, 95% CI 1.07–2.49), while in Caucasians the *1/*2 genotype was modestly protective vs *1/*1 (OR=0.76, 95% CI 0.61–0.95). No significant overall association emerged across all ethnicities, underscoring the importance of population context in interpreting this variant.

An earlier meta-analysis of 50 studies³³ meta-analysis of 50 studies
Zintzaras E et al. Alcohol-metabolizing enzyme gene polymorphisms, alcoholism, and pancreatitis. Pancreas, 2006 showed the ADH1C*2 allele associated with increased alcoholism risk overall (OR=1.32, 95% CI 1.12–1.57), with a much stronger effect in East Asians (OR=1.91, 95% CI 1.45–2.53), where ADH1C*1 is nearly universal and ADH1C*2 is the minority allele.

Alcohol Use Disorder:

A Turkish case-control study of 90 alcohol-dependent patients and 100 controls⁴⁴ Turkish case-control study of 90 alcohol-dependent patients and 100 controls
Kortunay S et al. ADH1C polymorphism and alcohol dependence risk in Turkish patients. Alcohol, 2012 found the ADH1C*2 allele frequency was nearly 3-fold higher in alcohol-dependent individuals (0.32 vs 0.11, p<0.0001), with the heterozygous *1/*2 genotype significantly overrepresented among dependent patients (42% vs 23%, p<0.0001). The *1/*1 CC genotype was more common among controls (77% vs 51%), suggesting the fast-metabolizing ADH1C*1 genotype may be somewhat protective against AUD in European-ancestry populations — possibly because faster ethanol clearance reduces alcohol's rewarding duration.

Combined ADH1B + ADH1C Effects:

An Israeli household study⁵⁵ An Israeli household study
Meyers JL et al. Alcohol-metabolizing genes and alcohol phenotypes in an Israeli household sample. Alcoholism, 2013 found that ADH1B and ADH1C jointly influence AUD risk in ways that neither gene captures alone. The absence of protective alleles for both genes was associated with OR=3.16 for AUD, compared to those possessing protective alleles for both, demonstrating that combined genotyping provides substantially better risk stratification than either gene in isolation.

Cardiovascular Benefits of Moderate Alcohol:

The gamma2 isoform confers a striking amplification of the cardiovascular benefits associated with moderate alcohol consumption.

In the Physicians' Health Study⁶⁶ In the Physicians' Health Study
Hines LM et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. NEJM, 2001, men who consumed at least one drink per day and were homozygous for gamma2 (TT) had relative risk of myocardial infarction of 0.14 (95% CI 0.04–0.45) compared to gamma1 homozygotes who drank the same amount — an 86% reduction. Gamma1/gamma1 moderate drinkers had RR=0.62, a much more modest 38% reduction. The gamma2 advantage was attributed to prolonged ethanol exposure and higher HDL elevation per drink.

A subsequent multi-cohort study⁷⁷ A subsequent multi-cohort study
Hines LM et al. ADH1C genotype, alcohol consumption, and plasma levels of HDL cholesterol and apolipoprotein AI. Circulation, 2005 confirmed that gamma2/gamma2 moderate drinkers had 5.3 mg/dL higher HDL than gamma1/gamma1 moderate drinkers (P=0.02), providing a plausible mechanism: slower ethanol oxidation prolongs alcohol's HDL-raising effect. This interaction was absent in premenopausal women and postmenopausal women using hormones, suggesting that endogenous estrogen already maximizes the HDL signal.

The Second Northwick Park Heart Study (n=2,773 men, 220 CHD events)⁸⁸ The Second Northwick Park Heart Study (n=2,773 men, 220 CHD events)
Younis J et al. ADH1C genotype, alcohol consumption, and risk of coronary heart disease. Atherosclerosis, 2005 found that gamma2/gamma2 men who drank just 1–3 units/week achieved HR=0.22 (95% CI 0.05–0.94) for CHD — a 78% reduction — compared to gamma1/gamma1 drinkers at the same modest intake. Crucially, the protective effect appeared at lower consumption levels than previously reported.

Practical Actions

For CC (ADH1C*1/*1) genotype: You carry the fast-metabolizing form of ADH1C on both chromosomes. In the context of heavy or regular alcohol consumption, this generates more acetaldehyde per drink compared to carriers of ADH1C*2. The practical implication is that your esophageal, hepatic, and upper aerodigestive tissues are exposed to more carcinogenic acetaldehyde per drink than in ADH1C*2 carriers. If you drink regularly, periodic upper endoscopy and liver function monitoring are clinically relevant. The cardiovascular benefit from moderate alcohol is real but smaller in your genotype than in ADH1C*2 carriers.

For CT (ADH1C*1/*2) genotype: You have one fast and one slow allele; your enzyme activity and acetaldehyde exposure are intermediate. Your cancer risk from drinking is lower than CC homozygotes, and your cardiovascular response to moderate alcohol is somewhat enhanced compared to CC carriers, though not as pronounced as TT individuals.

For TT (ADH1C*2/*2) genotype: You carry the slow-metabolizing form on both chromosomes. Ethanol is oxidized to acetaldehyde more slowly, producing less acute acetaldehyde per drink. This appears to lower your AUD risk in non-Asian populations (where this genotype is less common) and substantially amplifies the cardiovascular benefit of light-to-moderate drinking — the Physicians' Health Study found an 86% reduction in heart attack risk in TT moderate drinkers. However, in the context of alcohol misuse, ADH1C*2 is associated with higher AUD rates in some populations, possibly because slower metabolism allows ethanol to remain in the bloodstream longer, sustaining its reinforcing effects.

Interactions

The most important interaction is with ADH1B rs1229984 (His48Arg). ADH1B controls the overall speed of ethanol-to-acetaldehyde conversion at the beta subunit level, while ADH1C modulates it at the gamma subunit level. Combined ADH1B + ADH1C diplotype analysis consistently shows better AUD risk prediction than either gene alone. Carriers of protective alleles in both genes show OR=3+ lower AUD risk compared to those lacking both protective alleles.

The second key interaction is with ALDH2 rs671 (Lys487Glu). ALDH2 clears acetaldehyde after it's produced. ADH1C*1 fast production combined with ALDH2 deficiency creates the same acetaldehyde accumulation dynamic as seen with ADH1B His48 + ALDH2 deficiency — faster production and impaired clearance. This combination is relevant particularly in East Asian populations where ALDH2 deficiency is common.

The rs698 (Ile350Val) variant in ADH1C is in near-complete [linkage disequilibrium | When two alleles are inherited together more often than expected by chance, making them nearly interchangeable as genetic markers] with rs1693482, meaning the ADH1C*1 haplotype typically carries both the Arg272 and Ile350 alleles, and the ADH1C*2 haplotype carries Gln272 and Val350.

The SMAD3 gene encodes a central intracellular mediator of transforming growth factor-beta (TGF-β) signaling¹¹ transforming growth factor-beta (TGF-β) signaling
a pathway controlling cell growth, differentiation, and fibrosis in virtually every tissue, including the arterial wall. Within the vasculature, SMAD3 governs vascular smooth muscle cell (VSMC) behavior²² vascular smooth muscle cell (VSMC) behavior
whether smooth muscle cells remain quiescent in a healthy vessel wall or shift toward a proliferative, inflammatory phenotype that promotes plaque growth. The intronic variant rs17228212 at chromosome 15q22.33 was first identified in 2007 as a genome-wide significant locus for coronary artery disease³³ genome-wide significant locus for coronary artery disease
combined analysis of the Wellcome Trust Case Control Consortium and German Myocardial Infarction Family Study, but subsequent studies have produced complex and sometimes conflicting results, making it one of the more nuanced CAD-associated variants in the database.

The Mechanism

SMAD3 functions as the primary intracellular messenger when TGF-β binds its receptor complex on the cell surface. After receptor activation, SMAD3 is phosphorylated, complexes with SMAD4, and translocates to the nucleus where it regulates hundreds of target genes. In the vascular wall, this pathway has a paradoxical dual role⁴⁴ paradoxical dual role
TGF-β/SMAD3 can both protect against early atherosclerosis by suppressing inflammation, and accelerate advanced disease by driving VSMC phenotype switching and fibrosis.

Research by Civelek et al.⁵⁵ Civelek et al.
demonstrating that SMAD3 and TCF21 drive opposing gene programs in smooth muscle cells established that SMAD3 promotes a synthetic/inflammatory VSMC phenotype associated with plaque instability, while TCF21 pushes toward a fibrous cap phenotype that stabilizes plaques. The rs17228212 C allele may modulate SMAD3 expression levels through intronic regulatory elements⁶⁶ intronic regulatory elements
introns frequently harbor enhancers and chromatin-accessible regions that fine-tune transcription. A 2024 study demonstrated that individuals carrying the T allele had significantly higher density of SMAD3-positive cells in carotid endarterectomy specimens⁷⁷ significantly higher density of SMAD3-positive cells in carotid endarterectomy specimens
41±6/mm² vs 25±4/mm² for C allele carriers; p<0.001, suggesting the C allele reduces SMAD3 expression in plaque tissue.

A separate but related GWAS signal at the SMAD3 locus — rs17293632, in strong LD with rs56062135⁸⁸ rs17293632, in strong LD with rs56062135
D'=0.97, r²=0.94 — has been functionally characterized: its protective T allele disrupts an AP-1 transcription factor binding site in a SMAD3 intron 1 enhancer, reducing SMAD3 expression and VSMC proliferation. The rs17228212 variant is not in strong LD with rs17293632⁹⁹ not in strong LD with rs17293632
they are independent signals at the same locus, suggesting potentially distinct regulatory mechanisms.

The Evidence

The discovery of rs17228212 came from Samani et al. in the genome-wide association study published as part of the Wellcome Trust Case Control Consortium¹⁰¹⁰ Samani et al. in the genome-wide association study published as part of the Wellcome Trust Case Control Consortium
combining 1,926 CAD cases with 2,938 controls plus 875 MI cases and 1,644 controls from the German MI Family Study, with a combined p-value of <1.3×10⁻⁶ and >80% probability of representing a true association. The combined odds ratio across discovery and replication cohorts was in the 1.21–1.33 range¹¹¹¹ 1.21–1.33 range
modest but consistent with most GWAS-identified common risk variants.

A 2024 Slovenian case-control study by Petrovic et al. enrolled 308 patients with >75% carotid stenosis and 573 controls without hemodynamically significant carotid disease¹²¹² Petrovic et al. enrolled 308 patients with >75% carotid stenosis and 573 controls without hemodynamically significant carotid disease
total n=881 unrelated Caucasians, finding the TT genotype significantly enriched in cases compared to controls (64.0% vs 56.4%). In logistic regression adjusted for age, sex, hypertension, diabetes, smoking, and hypercholesterolemia, the TT genotype had OR 4.05 (95% CI 1.10–17.75; p=0.037) vs CC¹³¹³ TT genotype had OR 4.05 (95% CI 1.10–17.75; p=0.037) vs CC
indicating CC carriers were substantially protected against advanced carotid plaque. The dominant model (any CC or CT vs TT) showed OR 3.60 (95% CI 1.15–15.45; p=0.045).

In a Spanish cohort of 1,897 rheumatoid arthritis patients¹⁴¹⁴ Spanish cohort of 1,897 rheumatoid arthritis patients
where chronic inflammation creates a high-risk cardiovascular environment, the C allele was associated with lower risk of cerebrovascular accident in anti-CCP negative patients (HR 0.36; 95% CI 0.14–0.94; p=0.038) and with lower carotid intima-media thickness (p=0.0094). This protective effect was absent in anti-CCP positive patients, suggesting autoimmune inflammatory status modifies the SMAD3 genotype effect¹⁵¹⁵ autoimmune inflammatory status modifies the SMAD3 genotype effect
inflammation may overwhelm the variant's effect on basal TGF-β signaling.

Replication has been inconsistent: studies in Pakistani¹⁶¹⁶ Pakistani
per-allele OR 1.22, p=0.19 and Iranian populations¹⁷¹⁷ Iranian populations
monomorphic, all TT found no significant associations with CAD. East Asian populations show near-zero C allele frequency (~0.07%), making the variant essentially uninformative in those groups.

The overall picture from the literature is that the C allele is more likely protective than risk-increasing for CAD and carotid atherosclerosis, consistent with the idea that lower SMAD3 expression in vascular tissue reduces VSMC proliferation and plaque progression. The original GWAS finding of C allele as a risk factor has not replicated consistently, and the mechanistic data aligns with C being protective.

Practical Actions

Given the mixed evidence, individuals with TT genotype (most common at ~56%) have no protective C allele and are at the population-average or modestly elevated risk for atherosclerotic disease mediated through TGF-β/SMAD3 signaling. This warrants attention to vascular risk factors that interact with this pathway — particularly omega-3 fatty acids, which modulate TGF-β signaling in vascular cells¹⁸¹⁸ omega-3 fatty acids, which modulate TGF-β signaling in vascular cells
EPA and DHA reduce inflammatory cytokine production and VSMC activation, and high-sensitivity CRP monitoring as an inflammation biomarker¹⁹¹⁹ high-sensitivity CRP monitoring as an inflammation biomarker
given SMAD3's role at the inflammation-fibrosis interface in atherosclerosis.

Individuals with CC genotype (~6%) carry two copies of the allele associated with lower SMAD3 expression in plaques and potentially reduced atherosclerotic progression — though the evidence does not yet support any specific supplement or pharmacologic intervention targeting this mechanism directly.

Interactions

The SMAD3 locus harbors at least two independent CAD-associated signals: rs17228212 (this variant) and rs56062135/rs17293632, which are in strong LD with each other but not with rs17228212. The rs17293632 C allele has been functionally characterized as increasing SMAD3 enhancer activity through AP-1 binding, and the protective T allele reduces SMAD3 expression in arterial smooth muscle cells. SMAD3 and TCF21²⁰²⁰ SMAD3 and TCF21
both CAD GWAS genes at separate loci have opposing effects on VSMC phenotype — SMAD3 promotes synthetic/inflammatory SMC states, while TCF21 drives fibrous differentiation. The combined genetic burden across SMAD3 and TCF21 variants may more completely characterize an individual's vascular smooth muscle cell plasticity and coronary disease risk.

Deep within the FADS gene cluster on chromosome 11, rs174537 sits in a regulatory region that acts as a master volume control for FADS1¹¹ FADS1
Fatty acid desaturase 1, also called delta-5 desaturase (D5D), the enzyme that converts DGLA to arachidonic acid in the omega-6 pathway and ETA to EPA in the omega-3 pathway. This single nucleotide change — G versus T — determines how much FADS1 enzyme your cells produce, and in turn how efficiently your body converts plant-based omega-3 and omega-6 fats into their biologically active long-chain forms. Because the Western diet overwhelmingly supplies omega-3 fats as the short-chain precursor alpha-linolenic acid (ALA) from flaxseed, chia, and walnuts, your FADS1 genotype directly determines whether that plant-based omega-3 reaches your cells as EPA and ultimately DHA.

The Mechanism

rs174537 does not change the FADS1 protein itself — it acts upstream. The T allele increases DNA methylation of the FADS1 promoter region²² increases DNA methylation of the FADS1 promoter region
Allele-specific methylation studies in CD4+ cells and leukocytes confirm rs174537 T allele associates with higher methylation at a CpG site in the FADS1 promoter (Chr11:61584894), silencing transcription, which reduces how much FADS1 messenger RNA is transcribed and ultimately how much FADS1 enzyme is produced. Eight CpG sites within a putative enhancer region between FADS1 and FADS2 also show significant allele-specific methylation linked to this SNP. Lower FADS1 expression means slower conversion of: - Dihomo-gamma-linolenic acid (DGLA) → arachidonic acid (AA) in the omega-6 pathway - Eicosatetraenoic acid (ETA) → eicosapentaenoic acid (EPA) in the omega-3 pathway G allele carriers produce more FADS1 enzyme, converting more precursor fatty acids into their long-chain products. The practical result: GG homozygotes have higher circulating AA and higher baseline EPA (from endogenous conversion of plant ALA); TT homozygotes have lower AA and substantially lower EPA.

The Evidence

The landmark finding came from a genome-wide association study of plasma PUFAs in 1,075 participants³³ genome-wide association study of plasma PUFAs in 1,075 participants
Tanaka et al. 2009, InCHIANTI Study, PLoS Genetics where rs174537 showed the strongest GWAS signal for arachidonic acid (p = 5.95×10⁻⁴⁶) and explained a remarkable 18.6% of all additive variance in AA levels — an unusually large effect for a common SNP. The same variant significantly associated with EPA levels (p = 1.07×10⁻¹⁴) and eicosadienoic acid (p = 6.78×10⁻⁹). Population data confirmed the clinical stakes: in a comparative study of European Americans and African Americans, TT homozygotes had AA levels 26% lower than GG carriers⁴⁴ TT homozygotes had AA levels 26% lower than GG carriers
Sergeant et al. 2012, British Journal of Nutrition: TT 6.3±1.0% vs GG 8.5±2.1% of total fatty acids; p=3.0×10⁻⁵. The AA/DGLA ratio (a direct measure of FADS1 enzyme activity) was nearly half in TT versus GG carriers (3.4 vs 6.5, p=2.2×10⁻⁷). The cardiovascular implications cut both ways. Higher FADS1 activity (GG) produces more AA — the omega-6 precursor to pro-inflammatory eicosanoids — and is linked to higher LDL cholesterol and elevated CAD risk in T2D patients⁵⁵ higher LDL cholesterol and elevated CAD risk in T2D patients
T2D with GG genotype: OR=1.76 (95%CI 1.14–2.72) for combined T2D+CAD; elevated plasma LDL and delta-6 desaturase activity. Meanwhile, lower FADS1 activity (TT) reduces AA production but also impairs the endogenous pathway to EPA, leaving TT carriers dependent on preformed EPA from marine sources. A 12-week fish oil intervention study⁶⁶ 12-week fish oil intervention study
Roke and Mutch, Nutrients 2014 found that T allele carriers had 48% lower baseline serum EPA compared to GG homozygotes (p=0.04), yet when given 1.8 g EPA+DHA daily, T allele carriers showed a significantly greater percentage increase in red blood cell EPA incorporation (p=9.1×10⁻³). This confirms that while T carriers start with lower EPA, they absorb and incorporate supplemental EPA effectively.

Practical Actions

For T allele carriers (GT and TT): because endogenous EPA synthesis from ALA is reduced, relying on plant-based omega-3 sources (flaxseed, chia, walnuts) is insufficient to maintain adequate EPA levels. Direct supplementation with preformed EPA and DHA from marine sources or algae-based supplements bypasses the impaired conversion step entirely. Target 2–4 g combined EPA+DHA daily for TT homozygotes; 1–2 g for GT heterozygotes. For GG homozygotes: higher FADS1 activity means dietary omega-6 converts more efficiently to AA. When background omega-6 intake is high (typical Western diet with sunflower, corn, or soybean oil), this efficiently produces excess AA and pro-inflammatory eicosanoids. Shifting the omega-6:omega-3 ratio — increasing marine omega-3 and reducing omega-6 cooking oils — is the most evidence-based dietary adjustment.

Interactions

rs174537 is in high linkage disequilibrium (r² > 0.8) with rs174547 and rs174546 in the same FADS1 haplotype block. These variants co-segregate and may produce additive effects on FADS1 expression. Carrying multiple minor alleles across the FADS1 cluster compounds the reduction in desaturase activity. The FADS1 locus also interacts with dietary omega-6 intake: high linoleic acid (LA) intake combined with efficient FADS1 (GG) preferentially drives AA production. Conversely, in TT carriers on a low marine omega-3 diet, the impaired conversion capacity creates a functional EPA/DHA deficiency even with adequate ALA intake. This gene-diet interaction means the same dietary pattern produces very different PUFA profiles depending on FADS1 genotype — a key argument for personalized omega-3 supplementation guidance.

The melanocortin-4 receptor (MC4R) sits at the heart of your brain's appetite regulation system. Located in the hypothalamus¹¹ hypothalamus
the brain region controlling hunger, satiety, and energy balance, MC4R acts as a critical satiety receptor — when activated by melanocortin hormones, it signals "stop eating" and increases energy expenditure. The rs17782313 variant lies 188 kilobases downstream of the MC4R gene, in a regulatory region²² regulatory region
intergenic DNA that controls gene expression without coding for protein that modulates how much MC4R your neurons produce.

This is the second strongest common obesity genetic signal³³ second strongest common obesity genetic signal
after FTO rs9939609, the most well-replicated obesity GWAS hit discovered in genome-wide association studies. Each copy of the C allele increases BMI by approximately 0.22 kg/m², and the effect is even stronger in children. But unlike FTO, which primarily affects thermogenesis⁴⁴ thermogenesis
heat production and baseline metabolic rate, MC4R variants work through appetite — specifically affecting meal size, food cravings, and the brain's response to satiety signals.

The Mechanism

The rs17782313 polymorphism is a single nucleotide change from T (thymine) to C (cytosine) in an intergenic regulatory element. Epigenetic studies⁵⁵ Epigenetic studies
MeQTL analysis examining DNA methylation quantitative trait loci show that the C allele is associated with increased DNA methylation at the MC4R promoter, leading to reduced MC4R gene expression in hypothalamic tissue. Lower MC4R expression means fewer satiety receptors — your brain becomes less sensitive to "stop eating" signals from the melanocortin system.

The melanocortin pathway works through leptin⁶⁶ leptin
a hormone produced by fat cells that signals energy stores to the brain. Leptin activates proopiomelanocortin (POMC) neurons, which produce alpha-melanocyte stimulating hormone (α-MSH). This hormone binds to MC4R receptors, triggering satiety and ramping up energy expenditure. When MC4R expression is reduced, this entire cascade becomes less effective — you need stronger satiety signals to feel full, and baseline "stop eating" tone is diminished.

GTEx database analysis⁷⁷ GTEx database analysis
Genotype-Tissue Expression project data confirms that rs17782313 modulates MC4R expression in brain regions including the basal ganglia, as well as in testis and ovary. The variant also upregulates expression of DNAJC27 (a gene near MC4R), which may contribute to its metabolic effects through mechanisms still being investigated.

The Evidence

The genetic association between rs17782313 and obesity is one of the most robust in human genetics. A 2020 meta-analysis⁸⁸ 2020 meta-analysis
pooling 61 studies with 80,957 obesity cases and 220,223 controls found that C allele carriers had an 18% increased risk of obesity (OR=1.18, 95% CI=1.15-1.21, p<0.001), with consistent effects across Europeans, East Asians, and children. The association was independent of age, sex, and geographic region — this is a universal human biology signal, not a population-specific artifact.

Beyond BMI, the variant affects metabolic health. A 2024 systematic review⁹⁹ 2024 systematic review
examining metabolic syndrome components confirmed associations with diabetes (independent of BMI), hypertension, and dyslipidemia. In a Korean cohort, C allele carriers had 1.29-fold higher diabetes risk even after adjusting for body weight, suggesting MC4R influences glucose metabolism through pathways beyond simple adiposity.

The behavioral phenotype is especially striking. C allele carriers consistently show:

• Higher appetite scores — meta-analysis of 7 studies¹⁰¹⁰ meta-analysis of 7 studies
  8,044 participants total found C allele associated with increased overall appetite and hunger ratings
• Elevated ghrelin — Kuwaiti cohort study¹¹¹¹ Kuwaiti cohort study
  252 participants showed C carriers had 18% higher plasma ghrelin (the "hunger hormone") compared to TT
• Emotional eating and binge eating — Chilean study¹²¹² Chilean study
  1,054 adults found C carriers had higher emotional eating scores and 2.18-fold increased odds of binge eating when depressed (OR=2.18, 95% CI=1.23-3.87)
• Stress-appetite interaction — Korean Genome Epidemiology Study¹³¹³ Korean Genome Epidemiology Study
  4,331 adults showed C allele only associated with higher BMI in individuals reporting high mental stress, with no effect under low stress

Macronutrient preferences also shift. Studies show C carriers tend toward higher fat and protein intake and lower carbohydrate consumption, though results vary by population and diet assessment method. Critically, MC4R affects meal size, not meal frequency¹⁴¹⁴ meal size, not meal frequency
signaling within individual eating episodes rather than timing between meals — C carriers eat larger portions when they do eat.

Practical Implications

If you carry one or two copies of the C allele, your brain's satiety system is working with a slightly muted signal. This doesn't mean weight gain is inevitable, but it does mean you're fighting a biological headwind that benefits from strategic management.

The POUNDS Lost trial¹⁵¹⁵ POUNDS Lost trial
2-year weight loss study with 738 participants revealed a critical gene-diet interaction: C allele carriers randomized to high-protein diets (25% of calories) experienced greater increases in appetite and food cravings compared to non-carriers, while those on average protein (15% of calories) showed no genetic difference. This suggests that very-high-protein diets — often recommended for satiety — may backfire in MC4R C carriers through mechanisms not yet understood.

The stress-eating connection is actionable. Since the genetic effect only manifests under high mental stress, stress management isn't just psychological self-care — it's metabolic risk reduction. Practices that lower cortisol and activate parasympathetic tone may literally silence the genetic risk.

Behavioral interventions targeting emotional eating and binge patterns show promise. Mindfulness-based interventions¹⁶¹⁶ Mindfulness-based interventions
systematic reviews of MBIs for obesity-related eating have demonstrated efficacy for reducing binge eating, emotional eating, and external eating — exactly the behavioral phenotypes elevated in C carriers. Teaching interoceptive awareness (recognizing true physiological hunger vs. emotional triggers) may be especially valuable when genetic satiety signals are weakened.

Interactions

FTO rs9939609: The combined effect¹⁷¹⁷ combined effect
documented in multiple populations is more than additive. In a Chinese Han cohort, individuals carrying neither FTO nor MC4R risk alleles had average BMI 25.9±4.9, those with one risk allele 26.4±5.1, two risk alleles 28.1±5.5, and three or four risk alleles 33.2±6.3 — a clear dose-response. A 2019 study found that carrying both FTO AA (or TA) and MC4R TC/CC genotypes conferred 2.45-fold increased obesity risk (95% CI=1.12-5.37) compared to carrying neither. These two loci work through different mechanisms (thermogenesis vs. appetite), so their effects compound. If you have both, prioritize interventions addressing both pathways — structured eating for appetite control plus thermogenic activity like strength training or cold exposure for FTO.

rs12970134 and rs571312: These are additional MC4R-region variants in linkage disequilibrium¹⁸¹⁸ linkage disequilibrium
genetic correlation where alleles are inherited together with rs17782313. Studies often analyze them as a haplotype. The three SNPs tag the same regulatory block affecting MC4R expression, so their effects overlap rather than add.

Dietary patterns: Mediterranean diet adherence¹⁹¹⁹ Mediterranean diet adherence
DASH score analysis modulates the genetic risk. In a Spanish cohort, MC4R rs17782313 was only associated with type 2 diabetes in individuals with low Mediterranean diet scores; high adherence neutralized the genetic effect. The protective elements appear to be overall dietary pattern quality rather than specific macronutrients — emphasizing whole foods, fiber, polyphenols, and meal regularity over processed hyperpalatable foods that hijack appetite pathways.

Your body cannot synthesize zinc — every atom must enter through the intestinal wall. The protein that makes this possible is ZIP4¹¹ ZIP4
Zrt/Irt-like Protein 4, encoded by SLC39A4 on chromosome 8q24.3; the dominant apical zinc importer on the brush border of duodenal and jejunal enterocytes. When both copies of SLC39A4 carry loss-of-function mutations, dietary zinc simply cannot cross the gut wall. The result — hereditary acrodermatitis enteropathica (AE)²² acrodermatitis enteropathica (AE)
A rare autosomal recessive disorder of zinc malabsorption presenting with the classic triad of periorificial and acral dermatitis, chronic diarrhea, and alopecia; incidence approximately 1 in 500,000 newborns globally — is universally fatal without treatment and completely manageable with it.

This missense variant falls within the extracellular N-terminal domain of ZIP4. The substitution alters a conserved residue at codon 99 (alanine to threonine), disrupting protein folding in the region responsible for zinc coordination and trafficking to the apical membrane. Heterozygous carriers have one functional SLC39A4 copy and absorb zinc adequately in normal conditions; their zinc status is clinically indistinguishable from non-carriers.

The Mechanism

ZIP4 is an eight-transmembrane zinc transporter with a large extracellular N-terminal ectodomain essential for function. Under zinc-replete conditions, the ectodomain is proteolytically shed as a regulatory response that limits further zinc import — a feedback loop that AE-associated mutations disrupt³³ AE-associated mutations disrupt
Kambe & Andrews, Mol Cell Biol, 2009 by preventing normal cleavage. Under zinc-deficient conditions, full-length ZIP4 is rapidly recruited to the apical membrane to maximize absorption.

Functional studies of AE-causing missense mutations show two dominant mechanisms depending on mutation location. Variants near the histidine-rich and proline-rich subdomains of the ectodomain cause ER retention with immature glycosylation — the protein misfolds and never reaches the cell surface⁴⁴ ER retention with immature glycosylation — the protein misfolds and never reaches the cell surface
Kuliyev et al., J Biol Chem, 2021. Transmembrane domain variants such as P200L and G539R reach the plasma membrane but lose zinc-responsive endocytosis, reducing zinc uptake Vmax to approximately 30% of wild-type⁵⁵ 30% of wild-type
Wang et al., Hum Mol Genet, 2004. Either mechanism produces functional zinc malabsorption sufficient to cause AE when homozygous.

The Evidence

Küry et al. 2002 (Nature Genetics)⁶⁶ Küry et al. 2002 (Nature Genetics) identified SLC39A4 as the causative gene for AE through linkage analysis and mutational screening of eight affected families. Subsequent cataloguing by Schmitt et al. 2009 (Human Mutation)⁷⁷ Schmitt et al. 2009 (Human Mutation) expanded the known mutation spectrum to 31 variants across the entire gene. Missense mutations are the most frequent class. Genotype-phenotype correlation is poor — identical mutations can present with variable severity — suggesting modifier genes or environmental factors modulate the clinical picture.

AE presents within the first 4–10 weeks of life in formula-fed infants and later in breastfed infants (human milk contains a ligand that facilitates zinc absorption despite reduced ZIP4 activity). Without treatment, progressive zinc deficiency causes immune failure, growth retardation, photosensitivity, and neurological deterioration.

Practical Actions

For homozygous individuals (TT genotype), lifelong zinc supplementation is the established treatment. Oral zinc gluconate, sulfate, or acetate at 5–10 mg elemental zinc per kg/day corrects the deficiency acutely; maintenance dosing of 1–2 mg/kg/day is used long-term. Response is typically rapid — skin lesions and diarrhea resolve within days of initiating supplementation.

For heterozygous carriers (CT genotype), zinc absorption is adequate under normal dietary conditions. No supplementation is required unless serum zinc falls below reference range, which may occur during pregnancy, illness, or restrictive diets that increase zinc demand.

Interactions

SLC39A4 pathogenic variants interact in compound heterozygosity. A person who carries this allele on one chromosome and a second SLC39A4 loss-of-function variant (such as rs121434288, rs121434290, or rs121434291) on the other chromosome has functional AE — effectively the same as being homozygous for one variant. The full zinc supplementation protocol applies to confirmed compound heterozygotes.

Zinc competes for intestinal absorption with copper, iron, and calcium. High-dose zinc therapy can deplete copper over time; monitoring of serum copper and ceruloplasmin is recommended during long-term high-dose zinc replacement.

TBX1¹¹ TBX1
T-box transcription factor 1, the master regulator of pharyngeal arch development encoded at chromosome 22q11.21 is best known as the gene whose haploinsufficiency causes DiGeorge syndrome²² DiGeorge syndrome
22q11.2 deletion syndrome, characterised by heart defects, immune deficiency from thymic hypoplasia, and palate abnormalities. Rare catastrophic TBX1 deletions displace entire developmental programmes. But common intronic variants like rs1978060 operate more subtly: they modulate how much TBX1 the cell transcribes, shifting developmental outcomes by degrees rather than eliminating them altogether.

The G allele of rs1978060 acts as a cis-expression quantitative trait locus (cis-eQTL) — it reduces TBX1 expression in tissues where TBX1 matters for skeletal and muscular patterning. Among the consequences, the one with the strongest population-level evidence is susceptibility to adolescent idiopathic scoliosis³³ adolescent idiopathic scoliosis
AIS, abnormal lateral spinal curvature appearing during the pubertal growth spurt, affecting ~3% of adolescents worldwide with a strong female predominance.

The Mechanism

TBX1 is expressed in the paraxial mesoderm and the pharyngeal arches during embryogenesis, directing the formation of the pharynx, thymus, parathyroids, aortic arch, and the musculoskeletal components of the cervical and thoracic spine. In post-natal life, residual TBX1 activity influences the maintenance of paraspinal musculature. When TBX1 expression is reduced — as the G allele cis-eQTL effect produces — paraspinal muscle fibres show altered proportions of fibre types, and the resulting asymmetric loading across the growing spine may initiate or accelerate curvature.

Li et al. 2021⁴⁴ Li et al. 2021 confirmed this mechanistic link directly: TBX1 protein was measurably reduced in paraspinal muscle biopsies from AIS patients compared with congenital scoliosis controls, and the degree of reduction correlated with curve magnitude (r = −0.519, p = 0.003). This dose-response relationship between TBX1 expression and curve severity is the clearest molecular evidence that the rs1978060 eQTL effect has functional consequences in living tissue.

TBX1's role in pharyngeal arch development — particularly formation of the Eustachian tube and middle ear structures — also makes it a plausible candidate for ear-infection susceptibility in the general population. The 23andMe multi-infection GWAS (Tian et al. 2017, >200,000 Europeans) identified the TBX1 locus in associations with childhood ear infections and myringotomy, consistent with subtle Eustachian tube geometry or mucosal immune variation downstream of reduced TBX1 expression.

The Evidence

The primary discovery came from Kou et al. 2019⁵⁵ Kou et al. 2019
Genome-wide association study identifies 14 previously unreported susceptibility loci for AIS in Japanese — Nature Communications, a meta-analysis of three GWAS studies comprising 79,211 Japanese individuals. Rs1978060 at Chr22q11.21 reached genome-wide significance (p < 5×10⁻⁸) and was accompanied by cis-eQTL evidence linking the G allele to lower TBX1 expression.

Replication followed in Li et al. 2021⁶⁶ Li et al. 2021
Genetic variant of TBX1 is functionally associated with AIS in the Chinese population — Spine, enrolling 1,725 female AIS patients and 2,600 healthy controls in a Chinese Han cohort. The G allele showed OR 1.12 per allele for AIS susceptibility, consistent with an additive effect. The tissue expression data in this study provides the strongest functional link: TBX1 mRNA was significantly lower in paraspinal muscle of AIS patients, and the correlation with Cobb angle held across the patient cohort.

The effect size (OR ~1.12) places this variant in the category of common variants with modest individual effects — typical for complex developmental traits where dozens of loci collectively shape risk. The G allele frequency of ~61% globally means a large proportion of the population carries at least one copy; population-level burden is therefore meaningful even with a small per-allele OR.

Practical Actions

The variant's primary actionable consequence centres on scoliosis screening during the adolescent growth period. Early detection of scoliosis allows timely bracing, which is effective when started before curve progression. GG carriers — particularly adolescent girls, who are disproportionately affected by AIS — benefit most from awareness and systematic monitoring during the pubertal growth spurt. Note that a 2025 study (Dai et al., PMID 39206768) found rs1978060 does not significantly predict brace treatment outcome, suggesting the variant is most relevant for susceptibility awareness rather than treatment guidance.

For ear health, the TBX1 locus association with otitis media susceptibility observed in the large 23andMe GWAS (Tian et al. 2017) is consistent with a structural basis — Eustachian tube geometry and mucosal immune function — rather than a classical innate immune defect. Persistent or recurrent ear infections in G carriers may warrant audiological assessment and active management rather than watchful waiting.

Interactions

TBX1 lies at the centre of the 22q11.2 deletion region. The rs1978060 eQTL effect represents a common allelic series on the same biological axis as the rare 22q11.2 deletion. Carriers of the G allele do not have DiGeorge syndrome and will have normal thymic output, immune function, and cardiac anatomy — the eQTL effect is quantitative and tissue-limited, not equivalent to haploinsufficiency.

The most plausible interaction for future compound action research would involve other paraspinal development loci identified in the Kou 2019 GWAS (e.g., BNC2, CHD7, SOX9/KCNJ2 loci at rs10738445, rs1017861, rs12946942). Combined burden across multiple AIS susceptibility variants predicts risk better than any single locus, though specific compound action data for this combination are not yet published.

Every time blood vessels are injured, a cascade of proteins amplifies the initial clotting signal to rapidly seal the wound. Factor XI¹¹ Factor XI
Coagulation factor XI (FXI) is a serine protease that amplifies thrombin generation in the contact activation phase of coagulation. It circulates as a dimer in plasma and is activated by factor XIIa or thrombin on activated platelet surfaces sits near the middle of this cascade, acting as an amplifier that sustains thrombin generation after an initial clot forms. The rs201007090 variant — a single G-to-A substitution at codon 519 of the F11 gene — introduces a premature stop signal (Trp519Ter), truncating the Factor XI protein and producing little or no functional enzyme. The result is factor XI deficiency²² factor XI deficiency
Also called hemophilia C or Rosenthal disease, first described in the 1950s in families experiencing excessive bleeding with surgery and dental procedures, a mild-to-moderate inherited bleeding disorder.

The Mechanism

The F11 gene encodes a 607-amino-acid serine protease. The Trp519Ter nonsense mutation — caused by a single G>A transition at nucleotide position c.1556 of the canonical transcript (NM_000128.4) — converts a tryptophan codon (TGG) into a stop codon (TAG) at amino acid position 519. This truncates the catalytic domain, abolishing enzymatic activity. mRNAs carrying premature stop codons are typically degraded by nonsense-mediated decay³³ nonsense-mediated decay
A cellular surveillance pathway that degrades mRNAs with premature stop codons to prevent production of truncated, potentially dominant-negative proteins, so the mutant allele typically produces no protein rather than a truncated product.

Inheritance is autosomal recessive. Heterozygous carriers produce approximately 50% of normal FXI activity — enough for adequate hemostasis in most situations, but potentially insufficient under high-fibrinolysis surgical conditions. Homozygotes produce severely reduced or absent FXI activity, typically below 10 IU/dL, and are at significant risk of postoperative hemorrhage.

A critical clinical peculiarity of FXI deficiency is that FXI activity levels correlate poorly with actual bleeding tendency⁴⁴ FXI activity levels correlate poorly with actual bleeding tendency
Unlike hemophilia A or B, where factor activity predicts bleeding risk reliably, FXI-deficient patients with identical activity levels may have markedly different bleeding histories. Bleeding risk seems to depend partly on the specific mutation, platelet function, von Willebrand factor levels, and the fibrinolytic activity of the tissue being operated. This makes genotyping especially valuable — a molecular diagnosis helps predict surgical risk more reliably than activity measurements alone.

The Evidence

The clinical significance of nonsense mutations in F11 is well established. ClinVar classifies rs201007090 (G>A; Trp519Ter) as Pathogenic⁵⁵ ClinVar classifies rs201007090 (G>A; Trp519Ter) as Pathogenic
RCV000169241, 2-star review status — criteria provided, multiple submitters, no conflicts. Submitters include Fulgent Genetics and ISTH-SSC Genomics in Thrombosis and Hemostasis based on convergent pathogenicity criteria across three independent submitters. The variant is extremely rare globally: the A allele appears at a frequency of approximately 1 in 80,000 alleles (0.0000121) in gnomAD exomes, with higher representation in East Asian populations (approximately 0.00028).

Bleeding in FXI deficiency does not occur spontaneously — it is triggered specifically by trauma and surgery in anatomical sites with high intrinsic fibrinolytic activity⁶⁶ triggered specifically by trauma and surgery in anatomical sites with high intrinsic fibrinolytic activity
These include the urinary tract, oral cavity (tonsils, dental sockets), nasopharynx, and uterus. At these sites, tissue plasminogen activator (tPA) is abundant, so clots dissolve rapidly unless FXI-driven thrombin amplification provides sufficient fibrin crosslinking. By contrast, surgery at low-fibrinolysis sites (joints, muscle, skin) carries minimal bleeding risk even in severe deficiency.

Lewandowska and Connors, 2021⁷⁷ Lewandowska and Connors, 2021
Lewandowska MD, Connors JM. Hematol Oncol Clin North Am 2021;35:1157–1169 — comprehensive management review covering the diagnostic challenges of FXI deficiency, variability in treatment access, and thrombotic risks of FXI concentrate highlight that large volumes of fresh frozen plasma are required to achieve hemostatic FXI levels using FFP alone, and that FXI concentrate — while more concentrated — carries thrombotic risk requiring careful patient selection. Antifibrinolytics (tranexamic acid, epsilon-aminocaproic acid) are preferred for mucosal and dental procedures.

Practical Actions

For carriers of one Trp519Ter allele (heterozygotes), surgical planning is the main clinical priority. FXI activity should be measured preoperatively; procedures at high-fibrinolysis sites (tonsillectomy, urological surgery, dental extractions, uterine surgery) require specific hemostatic cover. Antifibrinolytic therapy (tranexamic acid) is first-line for mucosal and dental procedures. FXI concentrate or fresh frozen plasma is reserved for high-risk surgery. Surgical teams and anesthesiologists must be informed of FXI deficiency status before any procedure.

Homozygotes (AA genotype) have severe deficiency requiring management as for moderate hemophilia at all surgical sites. They should be followed by a specialist hematologist and carry emergency medical documentation.

Interactions

Factor XI deficiency interacts with medications that further suppress coagulation. Anticoagulants (warfarin, heparin, direct oral anticoagulants), antiplatelet agents (aspirin, clopidogrel), and NSAIDs all increase surgical bleeding risk disproportionately in FXI-deficient patients. FXI deficiency also intersects with von Willebrand disease — combined deficiency amplifies mucosal bleeding risk.

Other F11 pathogenic variants — including the Ashkenazi Jewish founder mutations at codons 117 (Glu117Stop; type II) and 283 (Phe283Leu; type III) — cause the same clinical syndrome through different molecular defects in the same gene. The Trp519Ter variant acts through the same premature termination mechanism as the type II mutation, though at a different position in the protein.

The rs2066808 variant lies within an intron of the STAT2 gene but sits immediately adjacent to IL23A on chromosome 12q13.3, and is the primary genome-wide association signal¹¹ genome-wide association signal
A variant reaching p < 5×10⁻⁸ in a population-scale disease study for the IL23A locus in psoriasis. IL23A encodes the p19 subunit — the half of interleukin-23 that is unique to IL-23 and absent from the closely related cytokine IL-12, which shares the p40 subunit. Because IL-23 is the master driver of Th17 cell differentiation²² Th17 cell differentiation
Th17 cells produce IL-17A and IL-17F, which stimulate keratinocyte hyperproliferation, a hallmark of psoriatic plaques, variants at this locus have direct clinical relevance not only for predicting psoriasis risk but also for understanding why anti-IL-23 biologics are among the most effective treatments available.

The Mechanism

The G allele at rs2066808 is an intronic variant within the STAT2/IL23A genomic neighbourhood; it does not change any amino acid in the IL-23 p19 protein. Instead, it acts as a regulatory or linkage tag³³ linkage tag
Variants in strong LD with a functional regulatory element will appear as GWAS hits even if they are not themselves the causal change for one or more functional elements that increase IL23A transcription in immune cells — particularly dendritic cells and macrophages in inflamed skin. Studies of uninvolved versus involved psoriatic skin found that IL23A is among the most significantly upregulated genes at active plaques (p < 10⁻⁹), making this locus functionally important beyond its statistical association. The elevated IL-23 drives naïve T cells toward the Th17 fate, causing sustained production of IL-17A, IL-17F, and IL-22, which together stimulate keratinocytes to proliferate abnormally and recruit additional neutrophils and inflammatory cells. This self-amplifying loop underlies both the chronic skin plaques of psoriasis and the synovitis of psoriatic arthritis.

The Evidence

The initial discovery came from a 2009 genome-wide scan⁴⁴ 2009 genome-wide scan
1,409 cases and 1,436 controls from a US/European population, followed up in 5,048 cases and 5,041 controls published in Nature Genetics, which genotyped 438,670 SNPs and identified rs2066808 as one of seven independent psoriasis risk loci (OR=1.34, combined p=1×10⁻⁹). The risk allele frequency in controls was approximately 7%, meaning the G allele is a true minor allele in most non-African populations. A subsequent independent cohort study⁵⁵ independent cohort study
Arthritis UK-funded case-control study of psoriatic arthritis specifically confirmed the association in psoriatic arthritis (p=9.1×10⁻⁷), establishing that this locus influences joint disease as well as skin disease.

Additional replication came from a Romanian cohort⁶⁶ a Romanian cohort
128 PsA patients and 116 healthy controls, with haplotype analysis of rs2066808 and rs11171806 confirming that carriers of the A allele (the major allele) were more frequent among PsA patients, and a multi-phenotype study⁷⁷ multi-phenotype study
Combined analysis of psoriasis severity, PsA, and type 2 diabetes in European cohorts linking IL23A variation to both psoriatic disease severity and metabolic comorbidities. Intriguingly, a Chinese Han study⁸⁸ Chinese Han study
206 IDD patients sequenced for IL23A and IL23R found rs2066808 associated with multiple sclerosis and other inflammatory demyelinating diseases, consistent with IL-23's broader role in CNS autoimmunity. The variant has also been associated with premature coronary artery disease⁹⁹ premature coronary artery disease
GEA study of 1,160 Mexican patients with CAD onset before 55 in men / 65 in women under a recessive model (GG versus AA+AG: OR=4.57), linking chronic IL-23-driven inflammation to accelerated atherosclerosis.

The biological relevance of this locus is powerfully validated by the therapeutic success of IL-23 p19 inhibitors. Guselkumab (approved 2017) and risankizumab (approved 2019) both selectively block the p19 subunit encoded by IL23A, achieving PASI-90 response rates¹⁰¹⁰ PASI-90 response rates
90% reduction in Psoriasis Area and Severity Index score — a stringent measure of near-complete clearance exceeding 70–75% in randomised trials, far outperforming earlier biologics.

Practical Actions

For individuals carrying the G allele — whether heterozygous AG or the rare homozygous GG — the key actions centre on early recognition of psoriatic disease, lifestyle factors that modulate IL-23 activity, and informed conversations with dermatologists or rheumatologists if symptoms arise. Carrying the G allele does not guarantee psoriasis, but it shifts the probability meaningfully, particularly in the context of known triggers such as streptococcal infection, stress, certain medications (beta-blockers, lithium, antimalarials), obesity, and smoking.

Dietary patterns that reduce systemic inflammation — particularly reducing ultra-processed food, refined carbohydrates, and excess saturated fat — may help lower baseline IL-23 signalling, though no intervention trial has directly targeted IL23A carriers. Omega-3 fatty acids (EPA and DHA from oily fish or supplements) have documented anti-Th17 effects and have been associated with reduced psoriasis severity in observational studies.

If psoriasis or psoriatic arthritis develops, carrying a confirmed IL23A risk allele provides biological rationale for discussing IL-23-targeted biologics (guselkumab, risankizumab, tildrakizumab) with your dermatologist or rheumatologist, since you carry a variant in the very gene encoding the cytokine these drugs block.

Interactions

The rs2066808 locus interacts within the IL-23 pathway with IL12B (rs3212227), which encodes the shared p40 subunit of both IL-12 and IL-23. Carrying risk alleles at both loci may compound Th17 polarisation. IL23R (rs11209026) encodes the receptor that IL-23 signals through; the rs11209026 R381Q protective allele reduces receptor sensitivity and is associated with substantially lower psoriasis and Crohn's disease risk — effectively acting as a counterweight to IL23A risk alleles. The rs2066808 variant is in moderate linkage disequilibrium with rs11171806, another IL23A region variant, forming a haplotype block that confers higher PsA risk than either variant alone in Romanian and other European cohorts.

The TFR2 gene encodes transferrin receptor 2, a sensor protein expressed primarily in hepatocytes and erythroid precursors that detects iron bound to transferrin in the bloodstream and helps calibrate the master iron hormone hepcidin¹¹ hepcidin
A peptide hormone made in the liver that controls how much iron is absorbed from the gut and released from recycling macrophages. rs2075674 is a synonymous coding variant in exon 16 of TFR2 — the nucleotide change (c.1851C>T, i.e. G→A on the genomic plus strand) does not alter the encoded alanine at position 617, but lies near the polypyrimidine tract of the adjacent intron and may influence mRNA splicing efficiency. It has been studied both as a tag SNP for the TFR2 locus in iron-trait GWAS and as an independent candidate in age-related macular degeneration²² age-related macular degeneration
AMD — the leading cause of vision loss in adults over 65; iron accumulates in the retinal pigment epithelium with aging and promotes oxidative damage to photoreceptors studies.

The Mechanism

TFR2 is expressed in the retinal pigment epithelium (RPE), the metabolic support layer for photoreceptors, in addition to its primary hepatic role. Iron in the RPE is essential for the visual cycle but accumulates excessively with aging, catalyzing the Fenton reaction³³ Fenton reaction
Fe²⁺ + H₂O₂ → Fe³⁺ + OH⁻ + OH• — generating hydroxyl radicals that damage lipid membranes, DNA, and proteins to generate reactive oxygen species that damage photoreceptors and RPE cells — a major driver of AMD pathogenesis. Variants in iron metabolism genes expressed in the RPE, including TFR2, are therefore plausible modulators of AMD risk through an oxidative stress pathway rather than through systemic iron dysregulation alone.

rs2075674 occupies a position in the TFR2 coding sequence near a splice-relevant regulatory element. Ensembl VEP annotates the A allele as a splice_polypyrimidine_tract_variant in addition to the synonymous coding change, suggesting the variant may subtly alter splicing of the downstream intron and thereby change TFR2 isoform ratios in tissues where alternative splicing is active. This mechanism is not yet verified by experimental splicing assays.

The Evidence

The AMD association for rs2075674 comes from two Polish and Chinese case-control studies. Wysokinski et al. 2014⁴⁴ Wysokinski et al. 2014
Disease Markers — 493 AMD cases and 171 controls; CC and TT genotypes (coding-strand notation equivalent to GG and AA on the plus strand) associated with AMD occurrence; TT genotype specifically enriched in obese AMD patients. The same group's earlier study with 278 patients found no interaction with smoking, suggesting the AMD association is not confounded by tobacco exposure.

Xu et al. 2022⁵⁵ Xu et al. 2022
Current Eye Research — 400 AMD patients (200 wet, 200 dry) and 200 controls in northeastern China; A allele of rs2075674 identified as a potential wet AMD risk factor, consistent with the direction reported by Wysokinski et al.

Importantly, a larger case-control study Shi et al. 2014⁶⁶ Shi et al. 2014
J Cardiovasc Med — 1,264 CHD cases and 1,264 controls in Chinese Han population; rs2075674 and rs7385804 used as TFR2 tag SNPs; no association with CHD risk or plasma ferritin found no effect on systemic iron markers, suggesting that rs2075674's potential functional effect is tissue-specific (retinal) rather than systemic. The iron GWAS evidence for the TFR2 locus derives primarily from the adjacent intronic variant rs7385804.

Practical Actions

For AA homozygotes, the most clinically relevant implication is the emerging AMD signal. Since the proposed mechanism is iron-driven retinal oxidative stress, the actionable response is to support antioxidant capacity in the eye and undergo regular retinal imaging — not to alter dietary iron intake, for which no specific effect has been demonstrated for this variant. The iron antioxidant minerals zinc and copper, and the carotenoids lutein and zeaxanthin (which concentrate in the retinal macula and quench reactive oxygen species), are the nutrients with the strongest evidence base for retinal protection.

Interactions

rs2075674 sits in the same TFR2 gene region as rs7385804, the intronic TFR2 variant with stronger evidence for systemic iron marker effects. The two variants tag partially overlapping LD blocks in the TFR2 locus on chromosome 7 and were used together as TFR2 tag SNPs in the Shi et al. CHD study. Combined carrier status at both loci could reflect broader TFR2 haplotype effects on iron sensing, though this has not been formally studied. The HFE C282Y variant (rs1800562) and TMPRSS6 Ala736Val (rs855791) operate in the same hepcidin-regulation pathway and would be expected to interact biologically with TFR2 variation in modulating iron homeostasis.

The kidney handles roughly 70% of daily uric acid elimination, and a network of transporters on the proximal tubule determines how much urate is reabsorbed back into the blood versus excreted into the urine. OAT4 (organic anion transporter 4)¹¹ OAT4 (organic anion transporter 4)
Encoded by SLC22A11, OAT4 sits on the apical (urine-facing) membrane of proximal tubule cells and exchanges urate for dicarboxylates like α-ketoglutarate is one of these gatekeepers — a lower-affinity but physiologically important urate reabsorber that works alongside the dominant transporter URAT1 (SLC22A12). The rs2078267 variant lies in an intron of SLC22A11 and is associated with altered OAT4 expression or function, with the C allele linked to higher serum urate concentrations and increased gout risk. This is the third major renal urate locus in GeneOps alongside ABCG2 Q141K (rs2231142)²² ABCG2 Q141K (rs2231142)
A secretory transporter on the gut and kidney that exports urate; the T allele reduces function by 53% and SLC2A9 Arg265His (rs3733591)³³ SLC2A9 Arg265His (rs3733591)
GLUT9, the dominant basolateral urate reabsorber in the proximal tubule, and each contributes independently to serum uric acid variance.

The Mechanism

OAT4 is a urate/dicarboxylate exchanger⁴⁴ urate/dicarboxylate exchanger
It swaps intracellular dicarboxylates (α-ketoglutarate, succinate) for luminal urate, pulling uric acid from the tubular fluid back into the cell expressed on the apical membrane of proximal tubule epithelial cells. While URAT1 (SLC22A12) handles the majority of urate reabsorption with higher affinity, OAT4 provides a parallel reabsorption pathway and also serves as an exit route for loop and thiazide diuretics into the tubular lumen — exchanging the diuretic molecule for urate in the process. This dual role is clinically significant: when diuretics are present, OAT4 activity increases urate reabsorption as a byproduct of diuretic secretion, explaining why thiazide and loop diuretics are well-known triggers of hyperuricemia and gout flares.

The rs2078267 variant is intronic (NM_018484.4:c.1059-957C>T), meaning it does not change the OAT4 protein sequence directly. Instead, the C allele likely enhances OAT4 expression or regulatory activity, increasing net urate reabsorption. In the landmark Global Urate Genetics Consortium (GUGC) meta-analysis⁵⁵ Global Urate Genetics Consortium (GUGC) meta-analysis
Köttgen et al. analyzed >140,000 individuals of European descent and identified 28 genome-wide significant urate loci, SLC22A11 was one of the ten replicated transporter loci, with the T allele associated with reduced serum urate (β = −0.073, p = 9.4 × 10⁻³⁸). In the ARIC study cohort⁶⁶ ARIC study cohort
McAdams-DeMarco et al. quantified the per-allele effect at 6.8 µmol/L (~0.11 mg/dL) higher serum urate per copy of the C allele.

The Evidence

The association between rs2078267 and serum urate is one of the most robustly replicated findings in urate genetics. The Köttgen 2013 GUGC study⁷⁷ Köttgen 2013 GUGC study
Köttgen A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145-54 established SLC22A11 as a genome-wide significant locus in >140,000 Europeans (p = 9.4 × 10⁻³⁸), with the 28 replicated loci collectively explaining 7.0% of serum urate variance. The C allele raises serum urate by approximately 6.8 µmol/L (0.11 mg/dL) per copy in an additive fashion.

A critical finding came from the ARIC gene-by-diuretic study⁸⁸ ARIC gene-by-diuretic study
McAdams-DeMarco MA, et al. A urate gene-by-diuretic interaction and gout risk. Arthritis Rheumatol. 2015;67(8):2201-9, which demonstrated a significant interaction between rs2078267 and diuretic use (p = 0.010). Individuals homozygous for the C allele who also took thiazide or loop diuretics had substantially elevated gout incidence, consistent with the molecular mechanism: diuretics compete for OAT4 transport, driving increased urate reabsorption as a side effect of diuretic secretion.

Cross-ancestry replication has been robust. An Indian GWAS⁹⁹ Indian GWAS
Giri AK, et al. Genome wide association study of uric acid in Indian population. Sci Rep. 2016;6:21440 confirmed the association at genome-wide significance in 4,834 individuals (p = 3.26 × 10⁻¹¹) with a larger effect size than in Europeans (β = −10.54 µmol/L for the protective allele). A New Zealand multi-ancestry study¹⁰¹⁰ New Zealand multi-ancestry study
Hollis-Moffatt JE, et al. Association analysis of SLC22A11 and SLC22A12 with gout in New Zealand. Arthritis Res Ther. 2014;16:R75 found the C allele conferred gout risk in Polynesians (OR 1.51) but not in local Europeans, suggesting ancestry-specific modifier effects.

The C allele frequency varies dramatically by ancestry — near-fixed in East Asians (~98%) and very common in Africans (~85%), moderate in South Asians (~59%) and Latinos (~76%), and lowest in Europeans (~47%). This means the variant contributes most to population-level urate variance in Europeans, where both genotypes are common enough to drive measurable differences.

Practical Actions

The clinical significance of this variant is most pronounced in two scenarios: baseline gout risk assessment and medication selection for hypertension. If you carry two copies of the C allele (CC genotype), your renal urate clearance is genetically reduced, making you more susceptible to hyperuricemia — especially if you also carry risk alleles in ABCG2 (rs2231142) or SLC2A9 (rs3733591). The gene-by-diuretic interaction is clinically actionable: CC carriers prescribed thiazide or loop diuretics for hypertension should have their uric acid levels monitored, and alternative antihypertensives (ACE inhibitors, ARBs, or calcium channel blockers) may be preferable if urate is already elevated.

Dietary purine restriction and adequate hydration become more important with this genotype. Tart cherry extract (500–1,000 mg daily) has demonstrated urate-lowering effects in clinical trials and may offer a low-risk complement to lifestyle measures. Vitamin C at 500 mg daily has modest uricosuric effects by competing with urate for renal reabsorption, though the magnitude (~0.5 mg/dL reduction) is smaller than pharmacological options.

Interactions

This variant operates in the same renal urate handling pathway as two other GeneOps variants. ABCG2 Q141K (rs2231142) reduces urate secretion from the gut and kidney — when combined with SLC22A11 CC (increased reabsorption), the net effect is a double hit: less urate exported and more reabsorbed, compounding hyperuricemia risk. SLC2A9 Arg265His (rs3733591) affects GLUT9, the dominant basolateral urate reabsorber — carrying risk alleles at both SLC2A9 and SLC22A11 amplifies the reabsorption side of the equation through two independent transporters.

The diuretic interaction documented for rs2078267 is mechanistically distinct from other urate loci. OAT4 physically transports diuretic molecules, creating a direct pharmacogenomic link that does not exist for ABCG2 or SLC2A9. This makes the SLC22A11 genotype particularly relevant when evaluating diuretic prescriptions.